Cancer Vaccines Market Size, Share & Industry Analysis
| 出版社 | Fortune Business Insights |
| 出版年月 | 2024年9月 |
| ページ数 | 136 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,850 |
| 種別 | 英文調査報告書 |
Growth Factors of Cancer Vaccines Market
The cancer vaccines market size was valued at USD 10.12 billion in 2023, and the market is now projected to grow from USD 12.14 billion in 2024 to USD 42.58 billion by 2032, exhibiting a CAGR of 17.0 % during the forecast period of 2024-2032.
がんワクチン市場規模は2023年に101億2,000万米ドルと評価され、現在市場は2024年の121億4,000万米ドルから2032年までに425億8,000万米ドルに成長すると予測されており、2024年から2032年の予測期間中に17.0%のCAGRを示します。
The COVID-19 pandemic has affected the cancer vaccines market in a major way, which has underlined the necessity of further and faster development of new vaccines. This devolved resources and focus on COVID-19 vaccines effectively halting cancer vaccine development. But it also created more innovations in vaccine science and cooperative relations between the academia and industry. The Covid-19 revealed to the world the pressing opportunity to fund cancer immunotherapy to provide better quality and effective treatment for patients with tumors. Therefore, users are eagerly awaiting further advancements to take place in the market.
Trends in the cancer vaccines market that has been seen in recent past is increase in personalized and therapeutic vaccines. The development in genomics and proteomics has provided the means of developing vaccines that can be targeted toward individual tumor associated markers. Also, the adaptation of the mRNA technology in its success of COVID-19 focus for higher efficacy and precise mechanisms starts among the new trends. Joint ventures between Biotech companies and research organizations are driving change, and the remedial nature of governmental support is opening up possibilities for clinical trials. Such trends have given rise to what can be called a new optimism in the development of cancer immunotherapy. The above-mentioned factors are driving the cancer vaccines market growth.
Some factors which are driving the market growth include increasing awareness of cancer vaccines and progress in the field of genomic studies, allowing to create vaccines for individual patients. Progress in immunotherapy and growing investment in biotechnology drive change, while favorable political and legal environments enhance clinical trials. Similarly, an increase in the number of cancer patients around the world as well as the need for new solutions also determine market growth. Moreover, increased success in the current experiments of vaccines that have been recently tested and the partnerships between the pharmaceutical firms and research institutions encourage the rate towards more efficient and specific cancer vaccines.
Comprehensive Analysis Cancer Vaccines Market
The market for cancer vaccines has been segmented on the basis of type, technology, indication and distribution. It includes the prophylactic vaccines that target and seek to stop or to slow down cancer formation, and there are the therapeutic vaccines which are used to manage cancers already formed. Some of the technologies used in the development of vaccines include molecular-based, vector-based as well as cell-based technologies which assume distinct methods of vaccine application and effectiveness. Some of the vaccines are developed to treat certain conditions including cervical, bladder, prostate and lung cancer among others. These are available in various forms including packed meals and give access to other distribution channels such as hospitals, government and organizational supply networks and other channels to allow integration to other healthcare systems.
Presently, cancer vaccines market share is dominated by North America. The former is attributed to factors such as, well-developed healthcare systems, R&D expenditure, and higher cancer treatment expenditure. The availability of large number of pharma majors and biotechnology companies coupled with strong regulatory framework strengthens the region’s position. Furthermore, the high incidence of cancer together with a well-developed clinical trial activity in North America proves that new vaccine products are in demand. These factors have cumulative effect towards enabling the region of North America to lead in the global cancer vaccines market.
Key players in this sector include Dendreon Pharmaceuticals LLC. (U.S.), Serum Institute of India Pvt. Ltd. (India), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Walvax Biotechnology Co., Ltd. (China), Synthaverse S.A. (Poland), Center of Molecular Immunology (Cuba), Ferring B.V. (Switzerland), Wantai BioPharm (China)
In 2023, the advanced therapeutic vaccine called BNT11 had been launched, produced by BioNTech as an mRNA vaccine. This innovative product is designed to address a number of cancer-associated antigens at once with the help of mRNA technology that has been used in developing Covid vaccines. BNT111, in this case, is equipped with the capacity of inciting a strong antibody response against several different cancers encoded by specific tumor antigens. Previous clinical trials on Provenge have suggested that early intervention of the drug has produced promising outcomes in treatment and care of cancer patients by offering them the most effective choices. This advance does signal a qualitative shift in cancer immunotherapy.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 17.0% from 2024-2032
Unit Value (USD billion)
Segmentation
By Type
• Preventive
• Therapeutic
By Technology
• Molecular-based
• Vector-based
• Cell-based
By Indication
• Cervical Cancer
• Bladder Cancer
• Prostate Cancer
• Lung Cancer
• Others
By Distribution Channel
• Hospitals
• Government & Organization Supply
• Others
By Region
• North America (By Type, By Technology, By Indication, By Distribution Channel, By Country)
o U.S.
o Canada
• Europe (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-Region)
o France
o Italy
o Spain
o U.K.
o Germany
o Rest of Europe
• Asia Pacific (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-Region)
o China
o Japan
o India
o Australia
o Southeast Asia
o Rest of Asia Pacific
• Latin America (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-region)
o Brazil
o Mexico
o Rest of Latin America
• Middle East & Africa (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-region)
o GCC
o South Africa
o Rest of Middle East & Africa)
Table of Contents
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Prevalence of Different Cancers, by Key Countries, 2023
4.2. Overview of Regulatory Scenario by Key Countries/Regions
4.3. Pipeline Analysis, Key Players
4.4. Key Industry Developments – Mergers, Acquisitions & Partnerships
4.5. New Product Launches
4.6. Impact of COVID-19 on Global Cancer Vaccines Market
5. Global Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032
5.1. Market Analysis, Insights and Forecast – By Type
5.1.1. Preventive
5.1.2. Therapeutic
5.2. Market Analysis, Insights and Forecast – By Technology
5.2.1. Molecular-based
5.2.2. Vector-based
5.2.3. Cell-based
5.3. Market Analysis, Insights and Forecast – By Indication
5.3.1. Cervical Cancer
5.3.2. Bladder Cancer
5.3.3. Prostate Cancer
5.3.4. Lung Cancer
5.3.5. Others
5.4. Market Analysis, Insights and Forecast – By Distribution Channel
5.4.1. Hospitals
5.4.2. Government & Organization Supply
5.4.3. Others
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Latin America
5.5.5. Middle East & Africa
6. North America Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032
6.1. Market Analysis, Insights and Forecast – By Type
6.1.1. Preventive
6.1.2. Therapeutic
6.2. Market Analysis, Insights and Forecast – By Technology
6.2.1. Molecular-based
6.2.2. Vector-based
6.2.3. Cell-based
6.3. Market Analysis, Insights and Forecast – By Indication
6.3.1. Cervical Cancer
6.3.2. Bladder Cancer
6.3.3. Prostate Cancer
6.3.4. Lung Cancer
6.3.5. Others
6.4. Market Analysis, Insights and Forecast – By Distribution Channel
6.4.1. Hospitals
6.4.2. Government & Organization Supply
6.4.3. Others
6.5. Market Analysis, Insights and Forecast – By Country
6.5.1. U.S.
6.5.2. Canada
7. Europe Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032
7.1. Market Analysis, Insights and Forecast – By Type
7.1.1. Preventive
7.1.2. Therapeutic
7.2. Market Analysis, Insights and Forecast – By Technology
7.2.1. Molecular-based
7.2.2. Vector-based
7.2.3. Cell-based
7.3. Market Analysis, Insights and Forecast – By Indication
7.3.1. Cervical Cancer
7.3.2. Bladder Cancer
7.3.3. Prostate Cancer
7.3.4. Lung Cancer
7.3.5. Others
7.4. Market Analysis, Insights and Forecast – By Distribution Channel
7.4.1. Hospitals
7.4.2. Government & Organization Supply
7.4.3. Others
7.5. Market Analysis, Insights and Forecast – By Country/Sub-region
7.5.1. France
7.5.2. Italy
7.5.3. Spain
7.5.4. U.K.
7.5.5. Germany
7.5.6. Rest of Europe
8. Asia Pacific Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032
8.1. Market Analysis, Insights and Forecast – By Type
8.1.1. Preventive
8.1.2. Therapeutic
8.2. Market Analysis, Insights and Forecast – By Technology
8.2.1. Molecular-based
8.2.2. Vector-based
8.2.3. Cell-based
8.3. Market Analysis, Insights and Forecast – By Indication
8.3.1. Cervical Cancer
8.3.2. Bladder Cancer
8.3.3. Prostate Cancer
8.3.4. Lung Cancer
8.3.5. Others
8.4. Market Analysis, Insights and Forecast – By Distribution Channel
8.4.1. Hospitals
8.4.2. Government & Organization Supply
8.4.3. Others
8.5. Market Analysis, Insights and Forecast – By Country/Sub-region
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. Australia
8.5.5. Southeast Asia
8.5.6. Rest of Asia Pacific
9. Latin America Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032
9.1. Market Analysis, Insights and Forecast – By Type
9.1.1. Preventive
9.1.2. Therapeutic
9.2. Market Analysis, Insights and Forecast – By Technology
9.2.1. Molecular-based
9.2.2. Vector-based
9.2.3. Cell-based
9.3. Market Analysis, Insights and Forecast – By Indication
9.3.1. Cervical Cancer
9.3.2. Bladder Cancer
9.3.3. Prostate Cancer
9.3.4. Lung Cancer
9.3.5. Others
9.4. Market Analysis, Insights and Forecast – By Distribution Channel
9.4.1. Hospitals
9.4.2. Government & Organization Supply
9.4.3. Others
9.5. Market Analysis, Insights and Forecast – By Country/Sub-region
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East & Africa Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032
10.1. Market Analysis, Insights and Forecast – By Type
10.1.1. Preventive
10.1.2. Therapeutic
10.2. Market Analysis, Insights and Forecast – By Technology
10.2.1. Molecular-based
10.2.2. Vector-based
10.2.3. Cell-based
10.3. Market Analysis, Insights and Forecast – By Indication
10.3.1. Cervical Cancer
10.3.2. Bladder Cancer
10.3.3. Prostate Cancer
10.3.4. Lung Cancer
10.3.5. Others
10.4. Market Analysis, Insights and Forecast – By Distribution Channel
10.4.1. Hospitals
10.4.2. Government & Organization Supply
10.4.3. Others
10.5. Market Analysis, Insights and Forecast – By Country/Sub-region
10.5.1. GCC
10.5.2. South Africa
10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Global Market Share Analysis (2023)
11.2. Company Profiles
11.2.1. Dendreon Pharmaceuticals LLC.
11.2.1.1. Overview
11.2.1.2. Products & Services
11.2.1.3. SWOT Analysis
11.2.1.4. Recent Developments
11.2.1.5. Strategies
11.2.1.6. Financials (Based on Availability)
11.2.2. Serum Institute of India Pvt. Ltd.
11.2.2.1. Overview
11.2.2.2. Products & Services
11.2.2.3. SWOT Analysis
11.2.2.4. Recent Developments
11.2.2.5. Strategies
11.2.2.6. Financials (Based on Availability)
11.2.3. Merck & Co., Inc.
11.2.3.1. Overview
11.2.3.2. Products & Services
11.2.3.3. SWOT Analysis
11.2.3.4. Recent Developments
11.2.3.5. Strategies
11.2.3.6. Financials (Based on Availability)
11.2.4. GlaxoSmithKline plc
11.2.4.1. Overview
11.2.4.2. Products & Services
11.2.4.3. SWOT Analysis
11.2.4.4. Recent Developments
11.2.4.5. Strategies
11.2.4.6. Financials (Based on Availability)
11.2.5. Walvax Biotechnology Co., Ltd.
11.2.5.1. Overview
11.2.5.2. Products & Services
11.2.5.3. SWOT Analysis
11.2.5.4. Recent Developments
11.2.5.5. Strategies
11.2.5.6. Financials (Based on Availability)
11.2.6. Synthaverse S.A.
11.2.6.1. Overview
11.2.6.2. Products & Services
11.2.6.3. SWOT Analysis
11.2.6.4. Recent Developments
11.2.6.5. Strategies
11.2.6.6. Financials (Based on Availability)
11.2.7. Center of Molecular Immunology
11.2.7.1. Overview
11.2.7.2. Products & Services
11.2.7.3. SWOT Analysis
11.2.7.4. Recent Developments
11.2.7.5. Strategies
11.2.7.6. Financials (Based on Availability)
11.2.8. Ferring B.V.
11.2.8.1. Overview
11.2.8.2. Products & Services
11.2.8.3. SWOT Analysis
11.2.8.4. Recent Developments
11.2.8.5. Strategies
11.2.8.6. Financials (Based on Availability)
11.2.9. Wantai BioPharm
11.2.9.1. Overview
11.2.9.2. Products & Services
11.2.9.3. SWOT Analysis
11.2.9.4. Recent Developments
11.2.9.5. Strategies
11.2.9.6. Financials (Based on Availability)
11.2.10. Dynavax Technologies Corporation
11.2.10.1. Overview
11.2.10.2. Products & Services
11.2.10.3. SWOT Analysis
11.2.10.4. Recent Developments
11.2.10.5. Strategies
11.2.10.6. Financials (Based on Availability)
Fortune Business Insights（フォーチュンビジネスインサイツ）は多様な産業を対象に市場調査を行い、市場動向、競争環境、将来予測などを盛り込んだ市場調査レポートを出版しています。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
| シングルユーザ | マルチユーザ | エンタープライズ |
| USD4,850 | USD5,850 | USD6,850 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 提供ファイル：印刷不可PDF
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 提供ファイル：印刷不可PDF＋Excel
- 同一企業内6名までレポートファイルのご共有が可能です。
- エンタープライズライセンス
- 提供ファイル：印刷可能PDF＋Excel
- 同一企業内人数無制限でレポートファイルのご共有が可能です。
- シングルユーザライセンス
- 納品方法
- Eメール
- 納期
- レポートタイトルにより異なります。詳細はお気軽にお問い合わせください。
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはFortune Business Insightsの日本の販売代理店として、Fortune Business Insightsのレポートを取り扱っております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にSEMABIZまでご連絡ください。
最新調査レポート